Recent advances of basic research and clinical application of lactoferrin as an antiviral reagent against chronic hepatitis C

Akito Nozaki, Katsuaki Tanaka, Atsushi Naganuma, Nobuyuki Kato

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Hepatitis C virus(HCV), discovered in 1989, is the major causative agent of chronic viral hepatitis. Most patients progress to liver cirrhosis and hepatocellular carcinoma. In the therapy of hepatitis C, only interferon has been used effectively as an anti-HCV reagent in Japan, but its effectiveness is limited to about 30% of cases. Using human hepatocyte cell line which could support efficient HCV replication, we previously found that lactoferrin inhibited HCV infection, and demonstrated that this inhibiting activity was due to the interaction of lactoferrin with HCV. Further analysis found that the carboxyl region of lactoferrin, which partially shows amino acid sequence homology to human CD81, specifically bound to the HCV E2 envelope protein, and identified a 33 amino acids as a critical binding domain of lactoferrin. On the other hand, it has been shown that bovine lactoferrin was effective in some patients with chronic hepatitis received an 8-week course of lactoferrin treatment. Further clinical trials showed that lactoferrin is a promising candidate for adjuvant therapy with interferon in patients with chronic hepatitis C.

Original languageEnglish
Pages (from-to)819-829
Number of pages11
JournalNihon rinsho. Japanese journal of clinical medicine
Volume60
Issue number4
Publication statusPublished - 2002

Fingerprint

Lactoferrin
Chronic Hepatitis C
Antiviral Agents
Hepacivirus
Research
Chronic Hepatitis
Interferons
Viral Envelope Proteins
Amino Acid Sequence Homology
Virus Diseases
Hepatitis C
Virus Replication
Liver Cirrhosis
Hepatocytes
Hepatocellular Carcinoma
Japan
Therapeutics
Clinical Trials
Amino Acids
Cell Line

Cite this

Recent advances of basic research and clinical application of lactoferrin as an antiviral reagent against chronic hepatitis C. / Nozaki, Akito; Tanaka, Katsuaki; Naganuma, Atsushi; Kato, Nobuyuki.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 60, No. 4, 2002, p. 819-829.

Research output: Contribution to journalArticle

@article{eef291d648904ec6bb72532962e9372d,
title = "Recent advances of basic research and clinical application of lactoferrin as an antiviral reagent against chronic hepatitis C",
abstract = "Hepatitis C virus(HCV), discovered in 1989, is the major causative agent of chronic viral hepatitis. Most patients progress to liver cirrhosis and hepatocellular carcinoma. In the therapy of hepatitis C, only interferon has been used effectively as an anti-HCV reagent in Japan, but its effectiveness is limited to about 30{\%} of cases. Using human hepatocyte cell line which could support efficient HCV replication, we previously found that lactoferrin inhibited HCV infection, and demonstrated that this inhibiting activity was due to the interaction of lactoferrin with HCV. Further analysis found that the carboxyl region of lactoferrin, which partially shows amino acid sequence homology to human CD81, specifically bound to the HCV E2 envelope protein, and identified a 33 amino acids as a critical binding domain of lactoferrin. On the other hand, it has been shown that bovine lactoferrin was effective in some patients with chronic hepatitis received an 8-week course of lactoferrin treatment. Further clinical trials showed that lactoferrin is a promising candidate for adjuvant therapy with interferon in patients with chronic hepatitis C.",
author = "Akito Nozaki and Katsuaki Tanaka and Atsushi Naganuma and Nobuyuki Kato",
year = "2002",
language = "English",
volume = "60",
pages = "819--829",
journal = "Nippon rinsho. Japanese journal of clinical medicine",
issn = "0047-1852",
publisher = "Nipponrinsho Co., Inc.",
number = "4",

}

TY - JOUR

T1 - Recent advances of basic research and clinical application of lactoferrin as an antiviral reagent against chronic hepatitis C

AU - Nozaki, Akito

AU - Tanaka, Katsuaki

AU - Naganuma, Atsushi

AU - Kato, Nobuyuki

PY - 2002

Y1 - 2002

N2 - Hepatitis C virus(HCV), discovered in 1989, is the major causative agent of chronic viral hepatitis. Most patients progress to liver cirrhosis and hepatocellular carcinoma. In the therapy of hepatitis C, only interferon has been used effectively as an anti-HCV reagent in Japan, but its effectiveness is limited to about 30% of cases. Using human hepatocyte cell line which could support efficient HCV replication, we previously found that lactoferrin inhibited HCV infection, and demonstrated that this inhibiting activity was due to the interaction of lactoferrin with HCV. Further analysis found that the carboxyl region of lactoferrin, which partially shows amino acid sequence homology to human CD81, specifically bound to the HCV E2 envelope protein, and identified a 33 amino acids as a critical binding domain of lactoferrin. On the other hand, it has been shown that bovine lactoferrin was effective in some patients with chronic hepatitis received an 8-week course of lactoferrin treatment. Further clinical trials showed that lactoferrin is a promising candidate for adjuvant therapy with interferon in patients with chronic hepatitis C.

AB - Hepatitis C virus(HCV), discovered in 1989, is the major causative agent of chronic viral hepatitis. Most patients progress to liver cirrhosis and hepatocellular carcinoma. In the therapy of hepatitis C, only interferon has been used effectively as an anti-HCV reagent in Japan, but its effectiveness is limited to about 30% of cases. Using human hepatocyte cell line which could support efficient HCV replication, we previously found that lactoferrin inhibited HCV infection, and demonstrated that this inhibiting activity was due to the interaction of lactoferrin with HCV. Further analysis found that the carboxyl region of lactoferrin, which partially shows amino acid sequence homology to human CD81, specifically bound to the HCV E2 envelope protein, and identified a 33 amino acids as a critical binding domain of lactoferrin. On the other hand, it has been shown that bovine lactoferrin was effective in some patients with chronic hepatitis received an 8-week course of lactoferrin treatment. Further clinical trials showed that lactoferrin is a promising candidate for adjuvant therapy with interferon in patients with chronic hepatitis C.

UR - http://www.scopus.com/inward/record.url?scp=0036548444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036548444&partnerID=8YFLogxK

M3 - Article

C2 - 11968795

AN - SCOPUS:0036548444

VL - 60

SP - 819

EP - 829

JO - Nippon rinsho. Japanese journal of clinical medicine

JF - Nippon rinsho. Japanese journal of clinical medicine

SN - 0047-1852

IS - 4

ER -